SORA

Advancing, promoting and sharing knowledge of health through excellence in teaching, clinical practice and research into the prevention and treatment of illness

Determinants of SARS-CoV-2 transmission to guide vaccination strategy in an urban area.

Brüningk, SC; Klatt, J; Stange, M; Mari, A; Brunner, M; Roloff, T-C; Seth-Smith, HMB; Schweitzer, M; Leuzinger, K; Søgaard, KK; et al. Brüningk, SC; Klatt, J; Stange, M; Mari, A; Brunner, M; Roloff, T-C; Seth-Smith, HMB; Schweitzer, M; Leuzinger, K; Søgaard, KK; Albertos Torres, D; Gensch, A; Schlotterbeck, A-K; Nickel, CH; Ritz, N; Heininger, U; Bielicki, J; Rentsch, K; Fuchs, S; Bingisser, R; Siegemund, M; Pargger, H; Ciardo, D; Dubuis, O; Buser, A; Tschudin-Sutter, S; Battegay, M; Schneider-Sliwa, R; Borgwardt, KM; Hirsch, HH; Egli, A (2022) Determinants of SARS-CoV-2 transmission to guide vaccination strategy in an urban area. Virus Evol, 8 (1). veac002. ISSN 2057-1577 https://doi.org/10.1093/ve/veac002
SGUL Authors: Bielicki, Julia Anna

[img]
Preview
PDF Published Version
Available under License Creative Commons Attribution Non-commercial.

Download (5MB) | Preview
[img] Archive (ZIP) (Supplementary data) Published Version
Available under License Creative Commons Attribution Non-commercial.

Download (10MB)

Abstract

Transmission chains within small urban areas (accommodating ∼30 per cent of the European population) greatly contribute to case burden and economic impact during the ongoing coronavirus pandemic and should be a focus for preventive measures to achieve containment. Here, at very high spatio-temporal resolution, we analysed determinants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission in a European urban area, Basel-City (Switzerland). We combined detailed epidemiological, intra-city mobility and socio-economic data sets with whole-genome sequencing during the first SARS-CoV-2 wave. For this, we succeeded in sequencing 44 per cent of all reported cases from Basel-City and performed phylogenetic clustering and compartmental modelling based on the dominating viral variant (B.1-C15324T; 60 per cent of cases) to identify drivers and patterns of transmission. Based on these results we simulated vaccination scenarios and corresponding healthcare system burden (intensive care unit (ICU) occupancy). Transmissions were driven by socio-economically weaker and highly mobile population groups with mostly cryptic transmissions which lacked genetic and identifiable epidemiological links. Amongst more senior population transmission was clustered. Simulated vaccination scenarios assuming 60-90 per cent transmission reduction and 70-90 per cent reduction of severe cases showed that prioritising mobile, socio-economically weaker populations for vaccination would effectively reduce case numbers. However, long-term ICU occupation would also be effectively reduced if senior population groups were prioritised, provided there were no changes in testing and prevention strategies. Reducing SARS-CoV-2 transmission through vaccination strongly depends on the efficacy of the deployed vaccine. A combined strategy of protecting risk groups by extensive testing coupled with vaccination of the drivers of transmission (i.e. highly mobile groups) would be most effective at reducing the spread of SARS-CoV-2 within an urban area.

Item Type: Article
Additional Information: © The Author(s) 2022. Published by Oxford University Press. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
SGUL Research Institute / Research Centre: Academic Structure > Infection and Immunity Research Institute (INII)
Journal or Publication Title: Virus Evol
ISSN: 2057-1577
Language: eng
Dates:
DateEvent
17 May 2022Published
16 February 2022Accepted
Publisher License: Creative Commons: Attribution-Noncommercial 4.0
Projects:
Project IDFunderFunder ID
Spark 190647Swiss National Science Foundationhttp://dx.doi.org/10.13039/501100001711
PubMed ID: 35310621
Web of Science ID: WOS:000770096600001
Go to PubMed abstract
URI: https://openaccess.sgul.ac.uk/id/eprint/114240
Publisher's version: https://doi.org/10.1093/ve/veac002

Actions (login required)

Edit Item Edit Item